نتایج جستجو برای: tp53

تعداد نتایج: 8206  

2014
Mariana Maschietto Richard D. Williams Tasnim Chagtai Sergey D. Popov Neil J. Sebire Gordan Vujanic Elizabeth Perlman James R. Anderson Paul Grundy Jeffrey S. Dome Kathy Pritchard-Jones Keith William Brown

PURPOSE The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional prognostic information. PATIENTS AND METHODS We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and analysed for TP53 muta...

Journal: :Anticancer research 2010
Thorsten H Ecke Horst H Schlechte Katrin Schiemenz Markus D Sachs Severin V Lenk Birgit D Rudolph Stefan A Loening

BACKGROUND We assessed the predictive value of TP53 mutations and prostate-specific antigen (PSA) for tumor progression in prostate cancer (PCa) patients. MATERIALS AND METHODS Ninety tumor tissue samples of patients with PCa from radical prostatectomy were used. Tumor progression was estimated biochemically by the PSA level (> 0.2 microg/l) or by detection of metastases. Screening for TP53 m...

2016
Daniel L. Faden Sarah T. Arron Chase M. Heaton Joseph DeRisi Andrew P. South Steven J. Wang

BACKGROUND Little is known regarding the etiology and genomic underpinnings of Oral Tongue Squamous Cell Carcinoma (OTSCC) in patients who lack traditional risk factors, yet the incidence is increasing. In particular, the rate, and role, of TP53 mutations in this cohort has been heavily debated in the literature. METHODS Tumor DNA from forty-three non-smokers with OTSCC underwent next generat...

2016
Sungjin Park Jinhyuk Lee Yon Hui Kim Jaheun Park Jung-Woog Shin Seungyoon Nam

While altered TP53 is the most frequent mutation in gastric cancer (GC), its association with molecular or clinical phenotypes (e.g., overall survival, disease-free survival) remains little known. To that end, we can use genome-wide approaches to identify altered genes significantly related to mutated TP53. Here, we identified significant differences in clinical outcomes, as well as in molecula...

2011
Jenni K Peltonen Kirsi H Vähäkangas Henni M Helppi Risto Bloigu Paavo Pääkkö Taina Turpeenniemi-Hujanen

BACKGROUND Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the world in developed countries. Despite the intense research in the area of squamous cell carcinomas of head and neck (HNSCC), long-term survival rate has not changed significantly in this malignancy during recent decades. METHODS In this study, we focused on TP53 mutations in specific regions, i...

2015
PAVLA BRACHOVA SAMUEL R. MUETING MATTHEW J. CARLSON MICHAEL J. GOODHEART ANNA M. BUTTON SARAH L. MOTT DONGHAI DAI KRISTINA W. THIEL ERIC J. DEVOR KIMBERLY K. LESLIE

Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some mutations create a non-functional protein, whereas others confer oncogenic activity, which we term 'oncomorphic'. Since mutations in TP53 occur in nearly all ovarian tumors, the objective of this study was to determine the relationship of oncomorphic TP53 mutations with patient outcomes in advanced serous ovarian...

2017
Tao Lu Paul Kim Yu Luo

Tp53, a stress response gene, is involved in diverse cell death pathways and its activation is implicated in the pathogenesis of Parkinson's disease. However, whether the neuronal Tp53 protein plays a direct role in regulating dopaminergic (DA) neuronal cell death or neuronal terminal damage in different neurotoxicant models is unknown. In our recent studies, in contrast to the global inhibitio...

2012
Simona Ognjanovic Ghyslaine Martel Carlos Manivel Magali Olivier Erica Langer Pierre Hainaut

The tumor suppressor gene TP53 is the most commonly mutated gene in human cancer. The reported prevalence of mutations in rhabdomyosarcoma (RMS) varies widely, with recent larger studies suggesting that TP53 mutations in pediatric RMS may be extremely rare. Overexpression of MDM2 also attenuates p53 function. We have performed TP53 mutation/MDM2 amplification analyses in the largest series anal...

Journal: :Blood 2016
Marwan Kwok Nicholas Davies Angelo Agathanggelou Edward Smith Ceri Oldreive Eva Petermann Grant Stewart Jeff Brown Alan Lau Guy Pratt Helen Parry Malcolm Taylor Paul Moss Peter Hillmen Tatjana Stankovic

TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL). Currently, therapies capable of providing durable remissions in relapsed/refractory TP53- or ATM-defective CLL are lacking. Ataxia telangiectasia and Rad3-related (ATR) mediates response to replication stress, the absence of w...

2014
Farhad BABAEI Seyed Ali AHMADI Ramin ABIRI Farhad REZAEI Maryam NASERI Mahmoud MAHMOUDI Rakhshande NATEGH Talat MOKHTARI AZAD

BACKGROUND The TP53 gene is one of the most frequently mutated genes amongst human malignancies, particularly TP53 codon 72 polymorphism. Furthermore, an association between the TP53 codon 72 variants and prostate cancer has been reported in several studies. Although some studies have indicated an association between the TP53 Arg/Arg variant and an increased risk for prostate cancer, other stud...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید